The carbonic anhydrase inhibitor acetazolamide exerts antidystonic effects in the dt(sz) mutant hamster

Previous studies suggested an involvement of gamma-aminobutyric acid (GABA)-mediated excitation by an enhanced efflux of bicarbonate ions in addition to retarded development of GABAergic inhibition in the syndrome of dt(sz) mutant hamsters, a model of paroxysmal dyskinesia in which dystonic episodes...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of pharmacology 2004-10, Vol.502 (1-2), p.105-108
Hauptverfasser: Richter, Angelika, Hamann, Melanie
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 108
container_issue 1-2
container_start_page 105
container_title European journal of pharmacology
container_volume 502
creator Richter, Angelika
Hamann, Melanie
description Previous studies suggested an involvement of gamma-aminobutyric acid (GABA)-mediated excitation by an enhanced efflux of bicarbonate ions in addition to retarded development of GABAergic inhibition in the syndrome of dt(sz) mutant hamsters, a model of paroxysmal dyskinesia in which dystonic episodes occur in response to stress. Acetazolamide blocks bicarbonate regeneration in neurons and can thereby reduce GABA-mediating excitation without affecting GABA-mediated inhibition. In the present study, the effects of acetazolamide (15-60 mg/kg, i.p.) on severity of dystonia were therefore examined in dt(sz) hamsters. Acetazolamide significantly reduced the severity of dystonia at a dose of 60 mg/kg. These data are in line with several case reports from patients with paroxysmal dystonia, suggesting that acetazolamide can be useful in the treatment of this movement disorder. The mechanism of the antidystonic efficacy of acetazolamide has to be examined by further studies.
doi_str_mv 10.1016/j.ejphar.2004.08.017
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_66941373</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66941373</sourcerecordid><originalsourceid>FETCH-LOGICAL-p122t-f7245dcf25122696c6d48d67c729078b7492807e3935a5c6d1c9693c8666dde13</originalsourceid><addsrcrecordid>eNo1kMtOwzAQRb0A0VL4A4S8QrBIsB0_4iVCvKRKbMo6cuwJcZVHsR2J9uuJoKxGd-6ZsxiErijJKaHyfpvDdteakDNCeE7KnFB1gpaEUJ4xrfUCnce4JYQIzcQZWlDBJSdaLNHnpgVsTajHwVtshnbvgomA_dD62qcxYGMhmcPYmd47wPANIcUZTN7tY_q9gqYBOy_9gNNsc-k2Hu5wP6WZwq3pY4JwgU4b00W4PM4V-nh-2jy-Zuv3l7fHh3W2o4ylrFGMC2cbJuYotbTS8dJJZRXTRJW14pqVREGhC2HE3FKrpS5sKaV0DmixQjd_3l0YvyaIqep9tNB1ZoBxipWUmtNCFTN4fQSnugdX7YLvTdhX_68pfgDd1GbB</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66941373</pqid></control><display><type>article</type><title>The carbonic anhydrase inhibitor acetazolamide exerts antidystonic effects in the dt(sz) mutant hamster</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Richter, Angelika ; Hamann, Melanie</creator><creatorcontrib>Richter, Angelika ; Hamann, Melanie</creatorcontrib><description>Previous studies suggested an involvement of gamma-aminobutyric acid (GABA)-mediated excitation by an enhanced efflux of bicarbonate ions in addition to retarded development of GABAergic inhibition in the syndrome of dt(sz) mutant hamsters, a model of paroxysmal dyskinesia in which dystonic episodes occur in response to stress. Acetazolamide blocks bicarbonate regeneration in neurons and can thereby reduce GABA-mediating excitation without affecting GABA-mediated inhibition. In the present study, the effects of acetazolamide (15-60 mg/kg, i.p.) on severity of dystonia were therefore examined in dt(sz) hamsters. Acetazolamide significantly reduced the severity of dystonia at a dose of 60 mg/kg. These data are in line with several case reports from patients with paroxysmal dystonia, suggesting that acetazolamide can be useful in the treatment of this movement disorder. The mechanism of the antidystonic efficacy of acetazolamide has to be examined by further studies.</description><identifier>ISSN: 0014-2999</identifier><identifier>DOI: 10.1016/j.ejphar.2004.08.017</identifier><identifier>PMID: 15464095</identifier><language>eng</language><publisher>Netherlands</publisher><subject>Acetazolamide - therapeutic use ; Animals ; Carbonic Anhydrase Inhibitors - therapeutic use ; Cricetinae ; Dose-Response Relationship, Drug ; Dystonia - drug therapy ; Dystonia - genetics ; Mutation</subject><ispartof>European journal of pharmacology, 2004-10, Vol.502 (1-2), p.105-108</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15464095$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Richter, Angelika</creatorcontrib><creatorcontrib>Hamann, Melanie</creatorcontrib><title>The carbonic anhydrase inhibitor acetazolamide exerts antidystonic effects in the dt(sz) mutant hamster</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>Previous studies suggested an involvement of gamma-aminobutyric acid (GABA)-mediated excitation by an enhanced efflux of bicarbonate ions in addition to retarded development of GABAergic inhibition in the syndrome of dt(sz) mutant hamsters, a model of paroxysmal dyskinesia in which dystonic episodes occur in response to stress. Acetazolamide blocks bicarbonate regeneration in neurons and can thereby reduce GABA-mediating excitation without affecting GABA-mediated inhibition. In the present study, the effects of acetazolamide (15-60 mg/kg, i.p.) on severity of dystonia were therefore examined in dt(sz) hamsters. Acetazolamide significantly reduced the severity of dystonia at a dose of 60 mg/kg. These data are in line with several case reports from patients with paroxysmal dystonia, suggesting that acetazolamide can be useful in the treatment of this movement disorder. The mechanism of the antidystonic efficacy of acetazolamide has to be examined by further studies.</description><subject>Acetazolamide - therapeutic use</subject><subject>Animals</subject><subject>Carbonic Anhydrase Inhibitors - therapeutic use</subject><subject>Cricetinae</subject><subject>Dose-Response Relationship, Drug</subject><subject>Dystonia - drug therapy</subject><subject>Dystonia - genetics</subject><subject>Mutation</subject><issn>0014-2999</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kMtOwzAQRb0A0VL4A4S8QrBIsB0_4iVCvKRKbMo6cuwJcZVHsR2J9uuJoKxGd-6ZsxiErijJKaHyfpvDdteakDNCeE7KnFB1gpaEUJ4xrfUCnce4JYQIzcQZWlDBJSdaLNHnpgVsTajHwVtshnbvgomA_dD62qcxYGMhmcPYmd47wPANIcUZTN7tY_q9gqYBOy_9gNNsc-k2Hu5wP6WZwq3pY4JwgU4b00W4PM4V-nh-2jy-Zuv3l7fHh3W2o4ylrFGMC2cbJuYotbTS8dJJZRXTRJW14pqVREGhC2HE3FKrpS5sKaV0DmixQjd_3l0YvyaIqep9tNB1ZoBxipWUmtNCFTN4fQSnugdX7YLvTdhX_68pfgDd1GbB</recordid><startdate>20041011</startdate><enddate>20041011</enddate><creator>Richter, Angelika</creator><creator>Hamann, Melanie</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20041011</creationdate><title>The carbonic anhydrase inhibitor acetazolamide exerts antidystonic effects in the dt(sz) mutant hamster</title><author>Richter, Angelika ; Hamann, Melanie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p122t-f7245dcf25122696c6d48d67c729078b7492807e3935a5c6d1c9693c8666dde13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Acetazolamide - therapeutic use</topic><topic>Animals</topic><topic>Carbonic Anhydrase Inhibitors - therapeutic use</topic><topic>Cricetinae</topic><topic>Dose-Response Relationship, Drug</topic><topic>Dystonia - drug therapy</topic><topic>Dystonia - genetics</topic><topic>Mutation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Richter, Angelika</creatorcontrib><creatorcontrib>Hamann, Melanie</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Richter, Angelika</au><au>Hamann, Melanie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The carbonic anhydrase inhibitor acetazolamide exerts antidystonic effects in the dt(sz) mutant hamster</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>2004-10-11</date><risdate>2004</risdate><volume>502</volume><issue>1-2</issue><spage>105</spage><epage>108</epage><pages>105-108</pages><issn>0014-2999</issn><abstract>Previous studies suggested an involvement of gamma-aminobutyric acid (GABA)-mediated excitation by an enhanced efflux of bicarbonate ions in addition to retarded development of GABAergic inhibition in the syndrome of dt(sz) mutant hamsters, a model of paroxysmal dyskinesia in which dystonic episodes occur in response to stress. Acetazolamide blocks bicarbonate regeneration in neurons and can thereby reduce GABA-mediating excitation without affecting GABA-mediated inhibition. In the present study, the effects of acetazolamide (15-60 mg/kg, i.p.) on severity of dystonia were therefore examined in dt(sz) hamsters. Acetazolamide significantly reduced the severity of dystonia at a dose of 60 mg/kg. These data are in line with several case reports from patients with paroxysmal dystonia, suggesting that acetazolamide can be useful in the treatment of this movement disorder. The mechanism of the antidystonic efficacy of acetazolamide has to be examined by further studies.</abstract><cop>Netherlands</cop><pmid>15464095</pmid><doi>10.1016/j.ejphar.2004.08.017</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0014-2999
ispartof European journal of pharmacology, 2004-10, Vol.502 (1-2), p.105-108
issn 0014-2999
language eng
recordid cdi_proquest_miscellaneous_66941373
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Acetazolamide - therapeutic use
Animals
Carbonic Anhydrase Inhibitors - therapeutic use
Cricetinae
Dose-Response Relationship, Drug
Dystonia - drug therapy
Dystonia - genetics
Mutation
title The carbonic anhydrase inhibitor acetazolamide exerts antidystonic effects in the dt(sz) mutant hamster
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T11%3A35%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20carbonic%20anhydrase%20inhibitor%20acetazolamide%20exerts%20antidystonic%20effects%20in%20the%20dt(sz)%20mutant%20hamster&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Richter,%20Angelika&rft.date=2004-10-11&rft.volume=502&rft.issue=1-2&rft.spage=105&rft.epage=108&rft.pages=105-108&rft.issn=0014-2999&rft_id=info:doi/10.1016/j.ejphar.2004.08.017&rft_dat=%3Cproquest_pubme%3E66941373%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66941373&rft_id=info:pmid/15464095&rfr_iscdi=true